Emergent Biosolutions
EBS
140 hedge funds and large institutions have $265M invested in Emergent Biosolutions in 2024 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 30 increasing their positions, 51 reducing their positions, and 31 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
27% more capital invested
Capital invested by funds: $208M → $265M (+$57M)
3% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 31
0.59% more ownership
Funds ownership: 58.06% → 58.66% (+0.59%)
1% less funds holding
Funds holding: 141 → 140 (-1)
11% less call options, than puts
Call options by funds: $7.37M | Put options by funds: $8.31M
41% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 51
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$17.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$15.6M |
| 3 |
OHA
Oak Hill Advisors
New York
|
+$10.1M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$7.74M |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
+$4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$16.8M |
| 2 |
Charles Schwab
San Francisco,
California
|
-$8.56M |
| 3 |
JP Morgan Chase
New York
|
-$5.9M |
| 4 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$5.31M |
| 5 |
CCM
Carronade Capital Management
Darien,
Connecticut
|
-$3.75M |
EBS Hedge Fund Activity: Q3 2024 in Review
140 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q3 2024, worth a combined $265M — up 27% from $208M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new EBS positions and 31 closed out — a net gain of 1 holder — while 30 added to existing stakes and 51 trimmed.
The largest buyer was Marshall Wace, adding an estimated $17.7M. The largest seller was BlackRock, cutting an estimated $16.8M.
- 140 institutional investors held Emergent Biosolutions (EBS) as of Q3 2024, down from 141 in Q2 2024.
- Funds reported $265M of Emergent Biosolutions stock for Q3 2024, up 27% quarter-over-quarter.
- 32 funds opened new Emergent Biosolutions positions in Q3 2024 and 31 closed out, a net change of +1 holder.
- The largest Emergent Biosolutions buyer in Q3 2024 was Marshall Wace, an estimated $17.7M added.
- The largest Emergent Biosolutions seller in Q3 2024 was BlackRock, an estimated $16.8M sold.
Based on aggregated 13F filings for Q3 2024.